How Can We Help You?

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Multiple Myeloma Trials

Select Clinical Trial

SWOG 1211: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

  • Men or women, 18 years or older, newly diagnosed with high risk, multiple myeloma. For additional criteria, call our Clinical Trials office at (910) 715-2200.

 

ECOG E1A11: Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

  • Men or women, 18 years or older, newly diagnosed with standard risk, multiple myeloma. For additional criteria, call our Clinical Trials office at (910) 715-2200.

 

MMY3008: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

  • Men or women, 18 years or older, newly diagnosed with multiple myeloma and not considered for high-dose chemotherapy. For additional criteria, call our Clinical Trials office at (910) 715-2200.
Specialties
Clara McLean House
Make a Donation
News & Events